Observational studyPloS one2026
Efficacy comparison of concurrent chemoradiotherapy alone versus concurrent chemoradiotherapy plus adjuvant chemotherapy in stage III Locally Advanced Cervical Cancer: A single-center, retrospective observational cohort study.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sequential chemoradiotherapyTranslational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study evaluated efficacy and safety of concurrent chemoradiotherapy (CCRT) versus CCRT plus adjuvant chemotherapy (CCRT+ACT) in 2018 Federation International of Gynecology and Obstetrics (FIGO) Stage III locally advanced cervical cancer (LACC) patients. This study provides clinical evidence to optimize treatment strategies for stage III LACC.
methodsA total of 72 patients diagnosed with stage III LACC were retrospectively enrolled from the Cancer Hospital of Guangdong Medical University between May 2018 and May 2024. They were divided into the CCRT group (n = 33) and the CCRT+ACT group (n = 39). Survival endpoints were analyzed using the Kaplan-Meier method with log-rank tests, and Cox proportional hazards regression models were applied to identify prognostic factors.
resultsThe 3-year OS (79.5% vs. 63.6%,P = 0.238) and PFS (56.4% vs. 45.5%,P = 0.706) rates showed no significant differences between the CCRT+ACT and CCRT groups. Kaplan-Meier survival analysis suggested that a positive lymph node size ≥ 10 mm (relative to a < 10 mm reference) may be associated with an increased hazard for mortality (HR = 8.235; P = 0.020) and disease progression (HR = 2.986; P = 0.020). Furthermore, abnormal post-brachytherapy SCC-Ag levels (> 1.5 ng/mL vs. ≤ 1.5 ng/mL reference) appeared to be strongly linked to adverse OS (HR = 13.641; P < 0.001) and PFS (HR = 4.722; P = 0.007). Regarding safety, CCRT+ACT did not increase grade 3-4 toxicities, suggesting a manageable safety profile.
conclusionWhile CCRT+ACT did not significantly improve survival in the un-selected stage III LACC population, a positive lymph node size of ≥ 10 mm and elevated post-brachytherapy SCC-Ag levels may serve as important prognostic indicators for adverse outcomes. These findings are hypothesis-generating, suggesting that integrating these factors into clinical risk assessment might aid in refining the identification of high-risk subsets who could potentially benefit from more personalized, intensified adjuvant strategies in future prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.